PIK3CA and neoplasm: Previous studies showed that activation of PD-1 signaling, indicative of immunosuppression, and the PI3K/AKT pathway correlates with EGFR TKI resistance (18), consistent with our observation of increased tumor-stroma interaction in the predicted-not-to benefit group.